HOME > TOP STORIES
TOP STORIES
-
TRENDS Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
REGULATORY Chuikyo Submits Recommendation for FY2016 Reimbursement Policy Reform, New Generic Incentive for Clinics Already Questioned
February 12, 2016
-
BUSINESS Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
-
BUSINESS Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
February 10, 2016
-
BUSINESS Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
February 9, 2016
-
REGULATORY Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
February 8, 2016
-
BUSINESS Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
February 5, 2016
-
BUSINESS Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
-
BUSINESS Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
February 3, 2016
-
BUSINESS Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
February 2, 2016
-
BUSINESS Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
-
BUSINESS Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
-
REGULATORY Suspended-but-Shipped Drugs Should Face 20% Price Cut, Chuikyo Member Says amid Kaketsuken Fuss
January 28, 2016
-
TRENDS 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
-
TRENDS Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
-
REGULATORY Gilead’s 2 Hep C Drugs Likely to Face Some 30% Price Cut under “Huge Seller” Re-Pricing: Jiho Estimate
January 25, 2016
-
ORGANIZATION JPMA Expels Kaketsuken over GMP Violations, Cover-Up
January 22, 2016
-
BUSINESS Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
January 21, 2016
-
REGULATORY “Huge Seller” Re-Pricing to Hit Sovaldi, Harvoni, Avastin, Plavix
January 20, 2016
-
REGULATORY Discussions on Market Price Survey for 2017 Revision Likely to Begin in March, Conclusion Expected in June
January 19, 2016
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
